about
Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.Longitudinal fMRI studies: Exploring brain plasticity and repair in MS.Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response.New treatment measurements for treatment effects on relapses and progression.Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis.Risk acceptance in multiple sclerosis patients on natalizumab treatment.Is inflammation important in early PPMS? a longitudinal MRI study.Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosisAbnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer studyMagnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis.Brain Atrophy in Multiple Sclerosis: Clinical Relevance and Technical Aspects.Neurofilament light chain level is a weak risk factor for the development of MS.Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study.THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.Localized grey matter atrophy in multiple sclerosis: a meta-analysis of voxel-based morphometry studies and associations with functional disability.Predictive markers of disease evolution after a CIS in everyday practice.Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS.Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis.Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study.Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe.Baseline MRI predicts future attacks and disability in clinically isolated syndromes.Defining high, medium and low impact prognostic factors for developing multiple sclerosis.Predictive value of early brain atrophy on response in patients treated with interferon βQuantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling.Response to botulinum toxin in a case of rigid spine syndrome.Adherence in multiple sclerosis (ADAMS): classification, relevance, and research needs. A meeting report.Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis.Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis.Lesion topographies in multiple sclerosis diagnosis: A reappraisal.Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis.Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates.Deep grey matter volume loss drives disability worsening in multiple sclerosis.'Brain reserve' and 'cognitive reserve' should always be taken into account when studying neurodegeneration - NO.Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria.Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI.Preliminary validation study of the Spanish version of the satisfaction with life scale in persons with multiple sclerosis.Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images.Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor.
P50
Q30965003-63642988-0B90-443E-B893-949EC87AAA07Q31032881-96596D12-4D66-47F8-B2F1-3BE729F87879Q31076601-D5F6ABB7-1040-4D89-BAF5-0B69B5362558Q33372487-6ED90E76-9F33-4063-9747-058B06BFC013Q34550413-2E03ABBF-C7AF-4042-A45E-5EF05D158B36Q35067882-5D07E46C-19A7-4400-BBC8-170BA933A179Q35489733-B4621724-5A9C-409A-A242-25C88439EE8AQ36143116-7C232774-235F-4563-B83B-CD5F758B6CFFQ36226260-6FBB270D-B7C1-4060-92E5-5598DBD6D127Q36226746-2FC9AAD2-3039-406B-AC35-3F6CA128CA06Q36341251-73597B90-BC27-49FA-A7DC-4246DF215D50Q37265143-70F47B91-7736-4F0F-84C5-CE014A308F4EQ37717025-C0FDC62C-3B6B-4239-B65E-03E565B88B76Q37860314-A25D0C01-868B-4180-B013-8A8859F5854CQ38091843-0528CA3D-68C1-47BF-9C84-E345FE46159EQ38216497-5D5F4D5A-0349-4D3D-9971-B28C62673326Q38298159-85A7362C-4688-4DD8-8994-59CE1EBC6445Q38411196-0BF76AA7-00A2-4A49-965A-F1121A8EF3C0Q38723319-E96E3378-740D-4B2C-A9BF-6AC2E810A9F8Q40044928-F02829C7-3514-4B36-A09C-3DD2959840ABQ40208644-A597CA49-D819-4B22-B9FB-0FE5470E4FB3Q40285067-BB344B53-CBFB-44EE-AE40-43C871C0308DQ41029094-01052E15-F57B-4005-9133-E6AF0C9E27CFQ41197913-06135CF5-E078-4FF5-983E-EB03BE9E3134Q41999269-DFD02419-B4E7-4093-8511-4CCBA92F9865Q43027842-E83B6468-0446-4D0D-8DB0-26E937BB3F61Q44954206-02473496-D671-468B-9868-0042CE8152BCQ46433079-041F2C88-FB1B-412E-8F2F-D60EA5D66699Q46689173-9C05EF26-268D-4525-AD7B-A9EBE791D69BQ47138738-FF714EAA-804D-4719-9506-BBBCC3D0A55EQ47237680-E6D7EFEB-1DE1-49E6-AD00-968582E86197Q47618323-D46AD856-E801-4BB1-903C-76D74988829CQ47866122-0B3DD5D0-A810-4F5E-A8E3-D031E2A29104Q47872919-19F77D33-EEA1-4DC1-A2BF-CA9F9DB245FFQ48099329-2981B438-61F7-4B78-9DDE-80E5C9E376D4Q48143686-9CBD1026-3EA0-40A6-A2F5-F81D7239D242Q48184654-A662F2CC-CB15-4AE0-B09A-576AAEDAB237Q48199092-1C35FB5C-2B42-4689-B165-0F18F2355B53Q48210503-5039C3D1-3DE5-4916-B959-88CD77611517Q48260470-3BFBD89A-43A0-4E4D-9C52-746EFCEA15F1
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-1589-2254
@en
name
Jaume Sastre Garriga
@en
Sastre-Garriga J
@ast
Sastre-Garriga J
@es
Sastre-Garriga J
@nl
type
label
Jaume Sastre Garriga
@en
Sastre-Garriga J
@ast
Sastre-Garriga J
@es
Sastre-Garriga J
@nl
altLabel
Sastre-Garriga J
@en
prefLabel
Jaume Sastre Garriga
@en
Sastre-Garriga J
@ast
Sastre-Garriga J
@es
Sastre-Garriga J
@nl
P106
P1153
6603920140
P31
P496
0000-0002-1589-2254